What does “extended genotyping” mean in the context of HPV testing?
HPV assays with partial
genotyping
Report multiple high-risk HPV (hr-HPV) genotypes in a single, pooled result1
BD OnclarityTM HPV Assay
with extended genotyping
Reports 6 hr-HPV genotypes individually and the other 8 hr-HPV genotypes in strategic, small groups1,2
May mask the true risk of CIN3+ disease due to HPV 31 and will likely lead to a one-year follow-up recommendation instead of an immediate colposcopy referral3–5
Can individually identify HPV 31, which poses a similar risk for cervical precancer and cancer as compared to HPV 184
Prohibits monitoring of genotype-specific HPV persistence beyond HPV 16 and 184
Can track genotype-specific hr-HPV persistence, the most important determinant of cervical cancer risk in women who test HPV-positive, regardless of HPV genotype4,6–8
Extended genotyping allows for a more precise way to measure your patient’s risk for developing cervical precancer and cancer vs. a pooled, high-risk assay.3,9
Learn more about extended genotyping with the BD Onclarity™ HPV Assay
CIN, cervical intraepithelial neoplasia; HPV, human papillomavirus; hr, high risk
1. Salazar K et al. J Am Soc Cytopath. 2019;8:284–92.
2. BD OnclarityTM HPV Assay US Package Insert [8089894].
3. Perkins RB et al. J Low Genit Tract Dis. 2020;24:102–31.
4. Bonde JH et al. J Low Genit Tract Dis. 2020;24(1):1–13.
5. Stoler MH et al. Am J Clin Pathol. 2019;151(4):433–42.
6. Elfgren et al. Am J Obstet Gynecol. 2017;216:264.e1-7.
7. Radley D et al. Hum Vaccin Immunother. 2016;12(3):768–72.
8. Bodily J, Laimins LA. Trends Microbiol. 2011;19(1):33–9.
9. Demarco M et al. E Clinical Medicine 22. 2020;100293.